We are live on ! Find out more
DCP

Davern Capital Partners Portfolio holdings

AUM $587M
This Fund
S&P 500
This Quarter Est. Return
+14.41%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$309M
AUM Growth
–
Cap. Flow
+$308M
Cap. Flow %
99.45%
Top 10 Hldgs %
90.61%
Holding
14
New
14
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 quarters
Top 10 Avg Time Held
0 quarters
Top 20 Avg Time Held
0 quarters

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$51.5M
2
BNTX icon
BioNTech
BNTX
+$37.4M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$35.6M
4
RPRX icon
Royalty Pharma
RPRX
+$32.1M
5
ARGX icon
argenx
ARGX
+$30.5M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PFE icon
1
Pfizer
PFE
$161B
$50.9M 16.44%
+2,042,242
New +$51.5M
2025 Q4
0 quarters
REGN icon
2
Regeneron Pharmaceuticals
REGN
$76.9B
$40.5M 13.08%
+52,420
New +$35.6M
2025 Q4
0 quarters
BNTX icon
3
BioNTech
BNTX
$24.4B
$35.3M 11.43%
+371,216
New +$37.4M
2025 Q4
0 quarters
RPRX icon
4
Royalty Pharma
RPRX
$25.3B
$32.5M 10.5%
+840,650
New +$32.1M
2025 Q4
0 quarters
ARGX icon
5
argenx
ARGX
$51.9B
$30M 9.7%
+35,685
New +$30.5M
2025 Q4
0 quarters
LEGN icon
6
Legend Biotech
LEGN
$3.62B
$23M 7.43%
+1,056,668
New +$30.3M
2025 Q4
0 quarters
ROIV icon
7
Roivant Sciences
ROIV
$25.6B
$22.3M 7.21%
+1,028,298
New +$20.3M
2025 Q4
0 quarters
IONS icon
8
Ionis Pharmaceuticals
IONS
$7.52B
$18.9M 6.1%
+238,477
New +$18M
2025 Q4
0 quarters
NTRA icon
9
Natera
NTRA
$57.8B
$18M 5.83%
+78,650
New +$16.4M
2025 Q4
0 quarters
LLY icon
10
Eli Lilly
LLY
$1.05T
$8.93M 2.89%
+8,307
New +$7.94M
2025 Q4
0 quarters
VRDN icon
11
Viridian Therapeutics
VRDN
$2.11B
$8.14M 2.63%
+261,615
New +$7.18M
2025 Q4
0 quarters
MLYS icon
12
Mineralys Therapeutics
MLYS
$2.07B
$7.64M 2.47%
+210,648
New +$8.45M
2025 Q4
0 quarters
CGON icon
13
CG Oncology
CGON
$5.66B
$6.73M 2.17%
+162,005
New +$6.7M
2025 Q4
0 quarters
ABVX
14
Abivax
ABVX
$7.69B
$6.54M 2.11%
+48,502
New +$5.29M
2025 Q4
0 quarters

Similar funds

ROC
Running Oak Capital Edina, Minnesota $587M AUM 0.28% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $587M AUM 22.12% 1-Year Est. Return
WPP
Whalerock Point Partners Providence, Rhode Island $587M AUM 29.61% 1-Year Est. Return
HNW
High Note Wealth Deephaven, Minnesota $586M AUM 23.56% 1-Year Est. Return
CFMC
Curbstone Financial Management Corp Manchester, New Hampshire $587M AUM 24.61% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $587M AUM 20.13% 1-Year Est. Return
RFG
REAP Financial Group Austin, Texas $586M AUM 22.63% 1-Year Est. Return
NI
Nuance Investments Kansas City, Missouri $588M AUM 6.93% 1-Year Est. Return

Davern Capital Partners's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for Davern Capital Partners, which disclosed 14 positions worth $309M. Its ten largest holdings account for 91% of the portfolio.

Its largest position is Pfizer: 2,042,242 shares worth $50.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Davern Capital Partners's largest Q4 2025 buy was Pfizer: 2,042,242 shares worth $50.9M.
  • Davern Capital Partners's ten largest holdings make up 91% of its $309M portfolio in Q4 2025.
  • Davern Capital Partners disclosed 14 positions in Q4 2025, its first 13F filing on record.

Based on Davern Capital Partners's 13F filing for Q4 2025, filed 13 Feb 2026.